Literature DB >> 22300723

Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission.

Guang-Jan Lin1, Ming-Chung Deng, Zeng-Weng Chen, Ting-Yu Liu, Ching-Wei Wu, Chih-Yuan Cheng, Maw-Sheng Chien, Chienjin Huang.   

Abstract

Classical swine fever (CSF) caused by the classical swine fever virus (CSFV) is a highly contagious swine disease resulting in large economical losses worldwide. The viral envelope glycoprotein E(rns) and E2 are major targets for eliciting antibodies against CSFV in infected animals. A Pichia pastoris yeast expressed E2 protein (yE2) has been shown to induce a protective immune response against CSFV challenge. The purpose of this study is to determine the optimal dose of yE2 and its efficacy on the prevention of virus horizontal transmission. A yeast-expressed E(rns) (yE(rns)) protein was also included to evaluate its immunogenicity. The yE(rns) vaccinated pigs seroconverted to CSFV-E(rns)-specific antibody but no neutralizing antibody was detected and none survived after challenge infection, suggesting yE(rns) and yE2 retain correct immunogenicity but only the yE2 is able to induce a protective immune response. All three doses of yE2 (200, 300, and 400μg) could elicit high titers of neutralizing antibodies and protective responses after challenge. The yE2/200 group demonstrated a mild fever response but recovered soon, and none of the yE2/300 and yE2/400 pigs became febrile. The optimal dose of yE2 was recommended to be 300μg of the total amount of secreted proteins. In addition, the yE2 vaccine could cross-protect from all three genotypes of viruses. Further, the yE2 vaccine efficacy in preventing virus horizontal transmission was evaluated by cohabitation of unimmunized sentinels 3 days after challenge infection. All the sentinel pigs were alive and had no clinical symptoms confirming yE2 vaccine could confer a protective immune response and prevent horizontal transmission of CSFV. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300723     DOI: 10.1016/j.vaccine.2012.01.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 as an Adjuvant.

Authors:  Yi-Gang Xu; Xue-Ting Guan; Zhong-Mei Liu; Chang-Yong Tian; Li-Chun Cui
Journal:  Appl Environ Microbiol       Date:  2015-03-27       Impact factor: 4.792

2.  Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Authors:  Murugan Subathra; Ponsekaran Santhakumar; Mangamoori Lakshmi Narasu; Syed Sultan Beevi; Sunil K Lal
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

3.  Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity.

Authors:  Rachel F Madera; Lihua Wang; Wenjie Gong; Yulia Burakova; Sterling Buist; Jerome Nietfeld; Jamie Henningson; Ada G Cino-Ozuna; Changchun Tu; Jishu Shi
Journal:  J Vet Sci       Date:  2018-05-31       Impact factor: 1.672

Review 4.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

5.  Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge.

Authors:  Rachel Madera; Wenjie Gong; Lihua Wang; Yulia Burakova; Karen Lleellish; Amy Galliher-Beckley; Jerome Nietfeld; Jamie Henningson; Kaimin Jia; Ping Li; Jianfa Bai; John Schlup; Scott McVey; Changchun Tu; Jishu Shi
Journal:  BMC Vet Res       Date:  2016-09-09       Impact factor: 2.741

6.  Identification of E2 with improved secretion and immunogenicity against CSFV in piglets.

Authors:  Huiling Xu; Yanli Wang; Guangwei Han; Weihuan Fang; Fang He
Journal:  BMC Microbiol       Date:  2020-02-04       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.